Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Le Buanec

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|March 18, 2000
Procedures for preparing biologically inactive, but immunogenic HIV-1 Tat protein (Tat toxoid) for human useH Le Buanec, B Bizzini
Idrugs : the Investigational Drugs Journal|June 16, 2005
Non-toxic immunogens for therapeutic anticytokine vaccinesD Zagury, H Le Buanec, B Bizzini, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|July 29, 1999
Lectin production by human T-lymphocytesA Lachgar, H Le Buanec, A Burny, et al.
Current Molecular Medicine|February 2, 2012
IL-10 producing regulatory B cells in mice and humans: state of the artJ-D Bouaziz, H Le Buanec, A Saussine, et al.
Cellular and Molecular Biology (Noisy-Le-Grand, France)|August 6, 2003
Therapeutic vaccine to control stromal tumor-induced immunosuppression in human uterine cervixc cancerH Le Buanec, L Cohen, S Paturance, et al.
Cytokine & Growth Factor Reviews|March 26, 2003
Active versus passive anti-cytokine antibody therapy against cytokine-associated chronic diseasesD Zagury, H Le Buanec, B Bizzini, et al.
The Journal of General Virology|September 28, 2004
Important B-cell epitopes for neutralization of human immunodeficiency virus type 1 Tat in serum samples of humans and different animal species immunized with Tat protein or peptidesE Moreau, G Belliard, C D Partidos, et al.
Annals of the Rheumatic Diseases|November 29, 2007
Early and long-lasting protection from arthritis in tumour necrosis factor alpha (TNFalpha) transgenic mice vaccinated against TNFalphaL Delavallée, H Le Buanec, N Bessis, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 28, 1999
A prophylactic and therapeutic AIDS vaccine containing as a component the innocuous Tat toxoidH Le Buanec, A Lachgar, B Bizzini, et al.
Journal of the National Cancer Institute|December 26, 2001
Selective activation of cervical microvascular endothelial cells by human papillomavirus 16-e7 oncoproteinR D'Anna, H Le Buanec, G Alessandri, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|March 18, 2000
Procedures for preparing biologically inactive, but immunogenic HIV-1 Tat protein (Tat toxoid) for human useH Le Buanec, B Bizzini
Idrugs : the Investigational Drugs Journal|June 16, 2005
Non-toxic immunogens for therapeutic anticytokine vaccinesD Zagury, H Le Buanec, B Bizzini, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|July 29, 1999
Lectin production by human T-lymphocytesA Lachgar, H Le Buanec, A Burny, et al.
Current Molecular Medicine|February 2, 2012
IL-10 producing regulatory B cells in mice and humans: state of the artJ-D Bouaziz, H Le Buanec, A Saussine, et al.
Cellular and Molecular Biology (Noisy-Le-Grand, France)|August 6, 2003
Therapeutic vaccine to control stromal tumor-induced immunosuppression in human uterine cervixc cancerH Le Buanec, L Cohen, S Paturance, et al.
Cytokine & Growth Factor Reviews|March 26, 2003
Active versus passive anti-cytokine antibody therapy against cytokine-associated chronic diseasesD Zagury, H Le Buanec, B Bizzini, et al.
The Journal of General Virology|September 28, 2004
Important B-cell epitopes for neutralization of human immunodeficiency virus type 1 Tat in serum samples of humans and different animal species immunized with Tat protein or peptidesE Moreau, G Belliard, C D Partidos, et al.
Annals of the Rheumatic Diseases|November 29, 2007
Early and long-lasting protection from arthritis in tumour necrosis factor alpha (TNFalpha) transgenic mice vaccinated against TNFalphaL Delavallée, H Le Buanec, N Bessis, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 28, 1999
A prophylactic and therapeutic AIDS vaccine containing as a component the innocuous Tat toxoidH Le Buanec, A Lachgar, B Bizzini, et al.
Journal of the National Cancer Institute|December 26, 2001
Selective activation of cervical microvascular endothelial cells by human papillomavirus 16-e7 oncoproteinR D'Anna, H Le Buanec, G Alessandri, et al.
Pageof 3